Background-Transapical aortic valve implantation has evolved to a reproducible therapeutic option for high-risk patients. Use of contrast dye (EE 104Ϯ78 mL, RE 93Ϯ46 mL) and the need to perform a balloon redilation were significantly reduced in the RE group. Thirty-day mortality decreased from 11.3% to 6.0%, and 1-year mortality improved significantly from 30.7% (EE) to 21.5% in the RE patients (Pϭ0.047).Multivariate logistic regression analysis revealed reduced vital capacity (Ͻ70%) and concomitant preoperative mitral regurgitation Ͼ1ϩ as the only independent predictors of 30-day mortality. Classic variables such as age, logistic EuroSCORE Ͼ30%, and STS score Ͼ15% failed to predict mortality.
Conclusions-Recent results with transapical aortic valve implantation indicate a progressive improvement in outcomesdespite an unchanged patient risk profile, which reflects a significant learning curve that includes a better understanding of optimal patient selection. Classic surgical risk factors fail to predict outcome, which indicates the need for new transapical aortic valve implantation-specific risk scores. (Circulation. 2011;124[suppl 1]:S124 -S129.)